Correction to: Dinutuximab beta in high-risk neuroblastoma: a profile of its use
- 301 Downloads
Correction to: Drugs Ther Perspect https://doi.org/10.1007/s40267-018-0522-2
The Acknowledgements section on the last page should read:
The manuscript was reviewed by: P.F. Ambros, Children’s Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; F.H. Felix, Pediatric Cancer Center, Hospital Infantil Albert Sabin, Fortaleza, Brazil; R. Kebudi, Division of Pediatric Hematology-Oncology, Cerrahpaşa Medical Faculty & Oncology Institute, Istanbul, Turkey; H.B. Lindsay, Pediatric Hematology/Oncology, Baylor College of Medicine, Houston, TX, USA; J. Morales, Pharmacy Department, Hospital Dr Luis Calvo Mackenna, Santiago, Chile. During the peer review process, EUSA Pharma (UK) Limited, the marketing-authorization holder of dinutuximab beta, was offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.
The original article has been corrected.